Citadel Advisors’s Alpine Immune Sciences Inc ALPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-64,500
Closed -$2.56M 15794
2024
Q1
$2.56M Buy
64,500
+64,200
+21,400% +$1.89M ﹤0.01% 5051
2023
Q4
$5.72K Buy
+300
New +$4.17K ﹤0.01% 13407
2023
Q1
Sell
-100
Closed -$735 15766
2022
Q4
$735 Buy
+100
New +$639 ﹤0.01% 14593

Citadel Advisors's ALPN Position: Q2 2024 in Review

Citadel Advisors sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 142,879 shares — an estimated $5.66M sold.

Citadel Advisors first reported a position in ALPN in Q4 2015 and held it in 7 quarters. The position peaked at $16.7M in Q4 2023. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

  • Citadel Advisors reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 142,879 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $5.66M.
  • Citadel Advisors first reported a position in Alpine Immune Sciences Inc in Q4 2015 and held it in 7 quarters.
  • Citadel Advisors's Alpine Immune Sciences Inc position peaked at $16.7M in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.